Pinnacle Home Care

pinnaclehomecare.net

Pinnacle Home Care is a full service Medicare Certified and Florida Licensed Home Health Company locally owned and operated by home health professionals who are passionate about delivering exceptional, quality care to the communities that we serve. With over 25 years of executive level home care leadership, you can feel confident that you are partnering with a highly respected organization that has your long-term interests in mind.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHANES THERAPEUTICS REVEALS A NEW BISPECIFIC ANTIBODY TECHNOLOGY PLATFORM AT BIO DIGITAL 2020

Phanes Therapeutics | June 16, 2020

news image

Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research in immuno-oncology announced today that it has developed a proprietary bispecific antibody technology platform, PACbodyTM, which enables construction of a bispecific antibody using any pair of monoclonal antibodies (mAbs) while maintaining the IgG-like structure. The technology was presented at the BIO Digital 2020."The beauty of the PACbodyTM bispecific antibody platform is that it's a 'pl...

Read More

MEDICAL

SESEN BIO PARTNERS WITH HIKMA PHARMACEUTICALS FOR THE REGISTRATION AND COMMERCIALIZATION OF VICINEUM

Sesen Bio | December 02, 2020

news image

Sesen Bio, a late-stage clinical organization creating focused on combination protein therapeutics for the therapy of patients with cancer, and Hikma Pharmaceuticals, a worldwide pharmaceutical organization and driving permitting partner in the Middle East and North Africa ("MENA") area spend significant time in the turn of events and commercialization of an expansive scope of great medicines, today declared that the organizations have gone into exclusive licensing agreement for the re...

Read More

CELL AND GENE THERAPY

WUXI ATU ANNOUNCES LAUNCH OF TESSA™ TECHNOLOGY TO IMPROVE SCALABILITY AND ACCESSIBILITY OF CELL AND GENE THERAPIES

WuXi AppTec | March 08, 2022

news image

WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA™). This technology is a state-of-the-art novel process for transfection-free, scalable manufacture of adeno-associated virus (AAV) at Good Manufacturing Practice (GMP) grade. Developed by OXGENE in the United Kingdom, a WuXi Advanced Therapies company, TESSA™ will expedite AAV manufacturing and significantly reduce the cost ...

Read More

CELL AND GENE THERAPY

BIOTECH STARTUP MEKONOS RAISES OVERSUBSCRIBED $25 MILLION ROUND TO OVERCOME PHARMA INDUSTRY'S CELL & GENE THERAPY DELIVERY HURDLES

Mekonos, Inc. | November 10, 2021

news image

Mekonos, a biotech company building the future of cell therapies on a chip, has raised $25M in an oversubscribed Series A round co-led by Reimagined Ventures, Fiscus Ventures, and PEAK6 Strategic Capital, a division of PEAK6 Investments. New institutional and strategic investors, including Section 32, Sands Capital, TDK Ventures, and the venture arm of Debiopharm, and previous investors, including Novartis Pharma AG (dRx Capital) and Elementum Ventures, also joined in the funding round that will...

Read More
news image

PHANES THERAPEUTICS REVEALS A NEW BISPECIFIC ANTIBODY TECHNOLOGY PLATFORM AT BIO DIGITAL 2020

Phanes Therapeutics | June 16, 2020

Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research in immuno-oncology announced today that it has developed a proprietary bispecific antibody technology platform, PACbodyTM, which enables construction of a bispecific antibody using any pair of monoclonal antibodies (mAbs) while maintaining the IgG-like structure. The technology was presented at the BIO Digital 2020."The beauty of the PACbodyTM bispecific antibody platform is that it's a 'pl...

Read More
news image

MEDICAL

SESEN BIO PARTNERS WITH HIKMA PHARMACEUTICALS FOR THE REGISTRATION AND COMMERCIALIZATION OF VICINEUM

Sesen Bio | December 02, 2020

Sesen Bio, a late-stage clinical organization creating focused on combination protein therapeutics for the therapy of patients with cancer, and Hikma Pharmaceuticals, a worldwide pharmaceutical organization and driving permitting partner in the Middle East and North Africa ("MENA") area spend significant time in the turn of events and commercialization of an expansive scope of great medicines, today declared that the organizations have gone into exclusive licensing agreement for the re...

Read More
news image

CELL AND GENE THERAPY

WUXI ATU ANNOUNCES LAUNCH OF TESSA™ TECHNOLOGY TO IMPROVE SCALABILITY AND ACCESSIBILITY OF CELL AND GENE THERAPIES

WuXi AppTec | March 08, 2022

WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA™). This technology is a state-of-the-art novel process for transfection-free, scalable manufacture of adeno-associated virus (AAV) at Good Manufacturing Practice (GMP) grade. Developed by OXGENE in the United Kingdom, a WuXi Advanced Therapies company, TESSA™ will expedite AAV manufacturing and significantly reduce the cost ...

Read More
news image

CELL AND GENE THERAPY

BIOTECH STARTUP MEKONOS RAISES OVERSUBSCRIBED $25 MILLION ROUND TO OVERCOME PHARMA INDUSTRY'S CELL & GENE THERAPY DELIVERY HURDLES

Mekonos, Inc. | November 10, 2021

Mekonos, a biotech company building the future of cell therapies on a chip, has raised $25M in an oversubscribed Series A round co-led by Reimagined Ventures, Fiscus Ventures, and PEAK6 Strategic Capital, a division of PEAK6 Investments. New institutional and strategic investors, including Section 32, Sands Capital, TDK Ventures, and the venture arm of Debiopharm, and previous investors, including Novartis Pharma AG (dRx Capital) and Elementum Ventures, also joined in the funding round that will...

Read More